Cloud-Based Drug Discovery Platforms Market size will attain USD 5.04 billion by 2030 growing at 10.8% CAGR

The Global Cloud-Based Drug Discovery Platforms Market size is expected to grow from USD 2.22 Billion in 2022 to USD 5.04 Billion by 2030, at a CAGR of 10.8% during the forecast period (2023-2030).

Market Overview:

Cloud computing technology gives customers access to storage, files, software, and servers through internet-connected devices such as computers, smartphones, tablets, and wearables. Cloud computing solution providers store and process data in a location that's separate from end-users.

Moreover, cloud computing provides the ability to store and access data and programs over the internet instead of on a hard drive. The usage of cloud-based drug discovery platforms in pharmaceutical and biotechnology firms allows collaboration with scientists and companies around the world. 

Top Key Players in the Cloud-Based Drug Discovery Platforms Market:

Accenture PLC (Ireland), Acelot Inc (US), Cloud Pharmaceuticals Inc. (US), Dassault Systemes (France), IBM Corporation (US), SAS Institute Inc.

(the US), Tata Consultancy Services Ltd. (India), WuXi AppTec (China), Collaborative Drug Discovery (CDD), SCYNEXIS Inc.

(the US), Medidata (US), Certara (US), Google (US), Cloudpharm, Amazon Web Services Inc. (the US) and other major players.

Get An Exclusive Sample Of The Cloud-Based Drug Discovery Platforms Market Report At This Link (Get The Higher Preference For Corporate Email ID): -

introspectivemarketresearch.com/request/14764

Market Dynamics and Factors for Cloud-Based Drug Discovery Platforms Market:

Drivers:

Increasing Implementation of Cloud-Based Platforms in The Healthcare Industry

With cloud-based drug discovery platforms, an individual with an internet connection and proper security codes can participate in the drug discovery process irrespective of geographic location. Additionally, it enables researchers globally, not only from different departments but also from different companies with different processes and cultures, to collaborate and exchange data and function as a team in the drug discovery process.

Moreover, with the adoption of cloud-based platforms, it became effortless for research institutions to organize several different drug discovery projects without having to upload all the information repeatedly. The data generated by the pharmaceutical companies is enormous and its management is a critical issue.

Opportunities:

Growing Healthcare Industry and The Rise in The Funding For R&D Activities

The growing healthcare industry and the rise in the funding for R&D activities to develop new drugs to treat diseases efficiently are creating better opportunities for software vendors. In recent years there has been a significant increase in the price of bringing new drugs to market, with estimates putting the cost as high as $1bn.

This situation has forced R&D laboratories to turn to new laboratory informatics technologies, to reduce spending and launch essential drugs in the market, faster. With the adoption of cloud-based drug discovery platforms, institutions can cut down the time required to discover new drugs.

Moreover, the report includes significant chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis.

Customize This Report: -

introspectivemarketresearch.com/custom-…arch/14764

Segmentation Analysis of the Cloud-Based Drug Discovery Platforms Market:

By Type, the Software as a Service (SaaS) segment is expected to dominate the market. SaaS reduced the time spent on the installation and configuration of software.

By Deployment Mode, the hybrid segment is expected to dominate the market. The rapid migration of applications over the cloud, and the emergence of more sophisticated threats are prompting businesses to adopt hybrid cloud-based solutions.

By Type

• Infrastructure As A Service {IaaS}
• Software As A Service {SaaS}
• Platform As A Service {PaaS}

By Deployment Mode

• Public
• Private
• Hybrid

By End User

• Pharmaceutical Vendors
• Biotech Vendors
• Contract Research Organizations
• Others

The report summarizes all the information collected and serves the customer's requirements. However, these market analyses help in understanding market growth at both global and regional levels.

For market data analysis, we have market panorama tools such as Market Dynamics, Competitor Analysis, PESTEL Analysis, SWOT Analysis, Porter Five Forces Analysis, Value Chain Analysis, Technology Roadmap and Evolution, Regulatory Framework, Price Trend Analysis, Patent Assnalysis, Covid-19 Impact Analysis, Russia-Ukraine War Impact and others.

Inquire : -

introspectivemarketresearch.com/inquiry/14764

Regional Analysis of the Cloud-Based Drug Discovery Platforms Market:

North America is expected to dominate the market during the forecast period. The growing number of pharmaceutical firms and a need to manage the huge data generated by this industry is the main factor driving the expansion of cloud-based drug discovery platforms in this region.

Moreover, countries such as the US and Canada have a wide presence of prominent cloud computing service providers. The growing prevalence of diseases and to find effective drugs quicker is stimulating pharmaceutical and biotechnology vendors to adopt cloud-based drug discovery platforms.

By Region     

• North America (U.S., Canada, Mexico)
• Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
• Western Europe (Germany, U.K., France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
• Asia-Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
• Middle East & Africa (Turkey, Saudi Arabia, Bahrain, Kuwait, Qatar, UAE, Israel, South Africa)
• South America (Brazil, Argentina, Rest of SA)

Key Industry Development:

In October 2021, Medidata declared the launch of its product Medidata Sensor Cloud Network at NEXT Global 2021. With this Medidata sensor cloud network, contract research organizations (CROs), analytics companies, device manufacturers, drug and vaccine developers, and academia will be able to collaborate and solve challenges associated with sensor integrations, standardization of sensor data, and the development of digital biomarkers and algorithms.

In October 2021, Certara, Inc. a global leader in biosimulation, declared the acquisition of Pinnacle 21, a prominent service provider of SaaS solutions for clinical data fitness, regulatory compliance, and submission readiness.

This acquisition is expected to boost Certara's ability to address vital decisions that further de-risk and accelerate the drug development process.

Acquire the Report: -

introspectivemarketresearch.com/checkou…_sid=14764